Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Refractory Ascitis Diagnosis by the Study of Labelled Albumin Pharmacokinetics (ARAM)

13 juni 2017 uppdaterad av: Assistance Publique - Hôpitaux de Paris

Refractory Ascitis Diagnosis by the Study of Labelled Albumin Pharmacokinetics Between Peritoneal and Vascular Compartments

Refractory ascites is an indication for liver transplantation, and includes ascites that is resistant to, or intractable by diuretic therapy (International Ascites Club). This definition is partly subjective; it can be established only a posteriori, following diuretic therapy administration to all patients, including those in whom untoward effects are prominent; and requires prolonged follow-up. An early diagnosis of refractory ascites would avoid giving diuretic therapy to patients in whom it will fail and identify rapidly candidates to liver transplantation. Such diagnosis could be done with a pharmacokinetic (PK) study of radiolabeled albumin between the peritoneal cavity and serum.

Studieöversikt

Detaljerad beskrivning

Main objective: assess the performances of PK parameters (transfer of labelled albumin) between peritoneal and vascular compartments, for the diagnosis of refractory ascitis, in patients with cirrhosis and abundant ascitis.

Design: proof of concept study. Interventional cross-sectional study in Beaujon Hospital (Clichy, France), 1 recruiting center and 1 non recruiting center.

Patients are recruited in the Hepatology department (Pr Valla) and PK exploration is performed in the nuclear medicine department (Pr Lebtahi) of Beaujon Hospital.

Description of intervention: diuretics treatment discontinuation 7 days before exploration for patients with sensitive ascitis, and more than 7 days for those with refractory ascitis. The day of exploration, the patients come to hospital and stay in lying position. One intra-veinous injection of 0,015 megabecquerel(MBq) /Kg labelled human serum albumin (Iode-125 (125-I), Séralb®CisBio), in compliance with market authorization, simultaneously to one intra-peritoneal injection of 200 MBq of labelled albumin (Technetium 99m (99m-Tc), Vasculocis®, Cisbio), off-label used. It follows 5 minutes mobilization of the patient (right and left lateral decubitus), then a scintigraphy will be performed using a gamma-camera Symbia T2 (Siemens®). Repeated blood (5 ml) and peritoneal ascitis (3 ml) samples are performed before injection and every 30 minutes for 6 hours (catheter in place). Diuretic treatment can be restarted the day after PK explorations. Patients are followed-up at 1 month by phone call (for the collection of adverse events).

Measurements : radioactivity measurements of 99m-Tc and 125-I in the biological samples are performed by a counter device in the nuclear medicine department (Wizard 3000, Packard®). Unidirectional transfer of labelled albumin (125-I) from vascular compartment (plasma-P) to peritoneal compartment (ascitis-A) (TPA), Unidirectional transfer of labelled albumin (99m-Tc) from peritoneal (A) to vascular compartment (P) (TAP), and the ratio TPA/TAP are calculated from these measurements using Matlab®.The gold standard is defined by the diagnosis of refractory ascitis performed before inclusion.

Statistical analyses: performances of the TAP, of the TPA, and of the ratio TPA/TAP for the diagnosis of refractory ascitis, will be computed using the Receiver Operating Characteristic (ROC) curve.

Number of patients : 30 patients (15 patients with refractory ascitis and 15 patients with sensitive or untreatable ascitis) will be included during a 24 months period (1 or 2 patients per month), and followed-up for 2 months. The PK explorations will be performed in nuclear medicine department not more than 4 weeks after inclusion. Total length of study will be of 26 months.

Studietyp

Interventionell

Inskrivning (Förväntat)

30

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Clichy, Frankrike, 92110
        • Hopital Beaujon

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 80 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • patients consulting in Hepatology department of Beaujon Hospital
  • aged 18 - 80 years old
  • cirrhosis due to alcoholic and/or dysmetabolic and/or viral (HBV or HCV) cause, pathologically or clinically/biologically/radiologically proven.
  • Volume of ascitis >5 L, either sensible or refractory to diuretics drugs according IAC criteria

Exclusion Criteria:

  • infection in the 2 weeks prior to inclusion (suspected or proven)
  • upper gastrointestinal bleeding du to portal hypertension in the 2 weeks prior to inclusion
  • transjugular intrahepatic portosystemic shunt (TIPS)
  • advanced hepatocellular carcinoma
  • hepatic transplantation
  • unability to stay lying for 6 hours
  • pregnancy / lactation
  • renal deficiency (creat. clearance < 60ml/min)
  • cardiac deficiency (≥ New York Heart Association (NYHA) III) or myocardial infarction (<3 months)
  • other cause of ascitis
  • contra-indication to human albumin (125-I) or vasculosis (99m-Tc) or other component of radio-pharmaceutics
  • no health insurance coverage
  • unability to go to the hospital for 1 day of exams
  • refuse to consent to study participation

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Diagnostisk
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Ascites in Patients With Cirrhosis
Patients will be further classified according to the refractory or sensitive ascitis
Intra-veinous injection of 0,015 MBq/Kg ; 0,5 to 2 mL injected over less than a minute
intra-peritoneal injection of 200 MBq of labelled albumin (99m-Tc, Vasculocis®, Cisbio) ; 5 ml injected over less than a minute

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Diagnosis of refractory ascitis according to International Ascites Club (IAC)
Tidsram: Exploration day (4 weeks after the inclusion)
Exploration day (4 weeks after the inclusion)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Measure of pharmacokinetics parameters : TPA
Tidsram: Exploration day (4 weeks after the inclusion)
radioactivity measurements of labelled albumin (125-I) in ascitis (peritoneal samples) and plasma (blood samples)
Exploration day (4 weeks after the inclusion)
Measure of pharmacokinetics parameters : TAP
Tidsram: Exploration day (4 weeks after the inclusion)
radioactivity measurements of labelled albumin (99m-Tc) in ascitis (peritoneal samples) and plasma (blood samples)
Exploration day (4 weeks after the inclusion)
Measure of pharmacokinetics parameters
Tidsram: Exploration day (4 weeks after the inclusion)
Ratio TPA/TAP
Exploration day (4 weeks after the inclusion)
adverse events
Tidsram: 1 month after exploration day
Phone call
1 month after exploration day
Proportion of patients in whom examination conditions and technical feasibility were completed
Tidsram: Exploration day (4 weeks after the inclusion)
adequate volume of ascites,stable state of patient, satisfactory spread of radiopharmaceuticals in the peritoneal compartment measure by scintigraphy, number of peritoneal and blood samples performed
Exploration day (4 weeks after the inclusion)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: VALLA Dominique, MD, Assistance Publique - Hôpitaux de Paris

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Förväntat)

1 september 2017

Primärt slutförande (Förväntat)

1 november 2019

Avslutad studie (Förväntat)

1 januari 2020

Studieregistreringsdatum

Först inskickad

20 juni 2016

Först inskickad som uppfyllde QC-kriterierna

27 juni 2016

Första postat (Uppskatta)

30 juni 2016

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

15 juni 2017

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

13 juni 2017

Senast verifierad

1 juni 2017

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • P140902
  • 2015-000157-20 (EudraCT-nummer)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera